[
    [
        {
            "time": "2018-04-15",
            "original_text": "FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia",
            "features": {
                "keywords": [
                    "FDA",
                    "Approves",
                    "Roche",
                    "Treatment",
                    "Acute Myeloid Leukemia"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-06-20",
            "original_text": "Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "Cancer",
                    "Approvals",
                    "PFE",
                    "ABBV",
                    "CHMP"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-10",
            "original_text": "Gauging Analysts’ Views on Tesaro Stock",
            "features": {
                "keywords": [
                    "Analysts",
                    "Views",
                    "Tesaro",
                    "Stock"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Gauging Analysts’ Views on Tesaro Stock",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-08-05",
            "original_text": "Understanding Tesaro’s Gross Margin Trend",
            "features": {
                "keywords": [
                    "Understanding",
                    "Tesaro",
                    "Gross",
                    "Margin",
                    "Trend"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Understanding Tesaro’s Gross Margin Trend",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        }
    ]
]